Back to User profile » Dr John Kane
Papers published by Dr John Kane:
Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia
Weiden PJ, Strand LN, Doane MJ, Arevalo C, McGrory JA, Achtyes ED, Harvey PD, Kane JM, Saklad SR, Trotter J, Velligan DI
Neuropsychiatric Disease and Treatment 2025, 21:2165-2181
Published Date: 23 September 2025
Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care
Correll CU, Rubio JM, Citrome L, Mychaskiw MA, Thompson S, Franzenburg KR, Suett M, Kotak S, Kane JM
Neuropsychiatric Disease and Treatment 2024, 20:1995-2010
Published Date: 19 October 2024
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia
Citrome L, Suett M, Franzenburg KR, Eshet R, Elgart A, Davis GL 3rd, Harary E, Tohami O, Mychaskiw MA, Kane JM
Neuropsychiatric Disease and Treatment 2024, 20:1901-1917
Published Date: 9 October 2024
A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 2: Negative Symptoms in Schizophrenia [Podcast]
Racher M, Carpenter W, Kane JM
Neuropsychiatric Disease and Treatment 2023, 19:1339-1345
Published Date: 2 June 2023
A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 1: Addressing Daily Functioning and Cognitive Impairments Associated with Schizophrenia [Podcast]
Larrauri CA, Harvey PD, Kane JM
Neuropsychiatric Disease and Treatment 2023, 19:1331-1338
Published Date: 2 June 2023
Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
Haider B, O'Sullivan AK, Bessonova L, Keane E, Achtyes E, Harvey PD, Kane JM, Saklad SR, Trotter JP, Claxton A, Polak T, McGrory J, Noori W, Sikora Kessler A, Yarlas A, Velligan D
Neuropsychiatric Disease and Treatment 2023, 19:623-634
Published Date: 17 March 2023
The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, Wang S, Richarz U, Gopal S, Kane JM
Neuropsychiatric Disease and Treatment 2023, 19:531-545
Published Date: 7 March 2023
Clozapine Management in Schizophrenia Inpatients: A 5-Year Prospective Observational Study of Its Safety and Tolerability Profile
de Filippis R, Gaetano R, Schoretsanitis G, Verde G, Oliveti CA, Kane JM, Segura-Garcia C, De Fazio P
Neuropsychiatric Disease and Treatment 2021, 17:2141-2150
Published Date: 1 July 2021
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations
Jackson R, Brams MN, Citrome L, Hoberg AR, Isaacson SH, Kane JM, Kumar R
Neuropsychiatric Disease and Treatment 2021, 17:1589-1597
Published Date: 24 May 2021
Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1
Sajatovic M, Ross R, Legacy SN, Correll CU, Kane JM, DiBiasi F, Fitzgerald H, Byerly M
Neuropsychiatric Disease and Treatment 2018, 14:1463-1474
Published Date: 8 June 2018
Initiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder – expert consensus survey part 2
Sajatovic M, Ross R, Legacy SN, Byerly M, Kane JM, DiBiasi F, Fitzgerald H, Correll CU
Neuropsychiatric Disease and Treatment 2018, 14:1475-1492
Published Date: 8 June 2018
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Solmi M, Pigato G, Kane JM, Correll CU
Drug Design, Development and Therapy 2018, 12:1215-1238
Published Date: 14 May 2018